172 related articles for article (PubMed ID: 35894278)
1. Treatment potential in APOL1-associated nephropathy.
Friedman DJ; Ma L; Freedman BI
Curr Opin Nephrol Hypertens; 2022 Sep; 31(5):442-448. PubMed ID: 35894278
[TBL] [Abstract][Full Text] [Related]
2. The evolving story of apolipoprotein L1 nephropathy: the end of the beginning.
Daneshpajouhnejad P; Kopp JB; Winkler CA; Rosenberg AZ
Nat Rev Nephrol; 2022 May; 18(5):307-320. PubMed ID: 35217848
[TBL] [Abstract][Full Text] [Related]
3. APOL1-Associated Nephropathy: A Key Contributor to Racial Disparities in CKD.
Freedman BI; Limou S; Ma L; Kopp JB
Am J Kidney Dis; 2018 Nov; 72(5 Suppl 1):S8-S16. PubMed ID: 30343724
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of Injury in APOL1-associated Kidney Disease.
Ma L; Divers J; Freedman BI
Transplantation; 2019 Mar; 103(3):487-492. PubMed ID: 30371607
[TBL] [Abstract][Full Text] [Related]
5. APOL1 Renal Risk Variants: Fertile Soil for HIV-Associated Nephropathy.
Kopp JB; Heymann J; Winkler CA
Semin Nephrol; 2017 Nov; 37(6):514-519. PubMed ID: 29110758
[TBL] [Abstract][Full Text] [Related]
6. The Impact of APOL1 on Chronic Kidney Disease and Hypertension.
Robinson TW; Freedman BI
Adv Chronic Kidney Dis; 2019 Mar; 26(2):131-136. PubMed ID: 31023447
[TBL] [Abstract][Full Text] [Related]
7. APOL1-Associated Collapsing Focal Segmental Glomerulosclerosis in a Patient With Stimulator of Interferon Genes (STING)-Associated Vasculopathy With Onset in Infancy (SAVI).
Abid Q; Best Rocha A; Larsen CP; Schulert G; Marsh R; Yasin S; Patty-Resk C; Valentini RP; Adams M; Baracco R
Am J Kidney Dis; 2020 Feb; 75(2):287-290. PubMed ID: 31601430
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide association studies suggest that APOL1-environment interactions more likely trigger kidney disease in African Americans with nondiabetic nephropathy than strong APOL1-second gene interactions.
Langefeld CD; Comeau ME; Ng MCY; Guan M; Dimitrov L; Mudgal P; Spainhour MH; Julian BA; Edberg JC; Croker JA; Divers J; Hicks PJ; Bowden DW; Chan GC; Ma L; Palmer ND; Kimberly RP; Freedman BI
Kidney Int; 2018 Sep; 94(3):599-607. PubMed ID: 29885931
[TBL] [Abstract][Full Text] [Related]
9. Host factors predisposing to kidney disease in people with HIV.
Hung RKY; Winkler CA; Post FA
Curr Opin HIV AIDS; 2023 Mar; 18(2):87-92. PubMed ID: 36722197
[TBL] [Abstract][Full Text] [Related]
10. An Acidic Environment Induces APOL1-Associated Mitochondrial Fragmentation.
Li D; Snipes JA; Murea M; Molina AJA; Divers J; Freedman BI; Ma L; Petrovic S
Am J Nephrol; 2020; 51(9):695-704. PubMed ID: 32866949
[TBL] [Abstract][Full Text] [Related]
11. Practical Considerations for APOL1 Genotyping in the Living Kidney Donor Evaluation.
Mena-Gutierrez AM; Reeves-Daniel AM; Jay CL; Freedman BI
Transplantation; 2020 Jan; 104(1):27-32. PubMed ID: 31449181
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia hits APOL1 in the kidney.
Grampp S; Krüger R; Lauer V; Uebel S; Knaup KX; Naas J; Höffken V; Weide T; Schiffer M; Naas S; Schödel J
Kidney Int; 2023 Jul; 104(1):53-60. PubMed ID: 37098381
[TBL] [Abstract][Full Text] [Related]
13. A focus on the association of Apol1 with kidney disease in children.
Ekulu PM; Nkoy AB; Adebayo OC; Kazadi OK; Aloni MN; Arcolino FO; Ngiyulu RM; Gini JE; Lepira FB; Van den Heuvel LP; Levtchenko EN
Pediatr Nephrol; 2021 Apr; 36(4):777-788. PubMed ID: 32253519
[TBL] [Abstract][Full Text] [Related]
14. High risk APOL1 genotypes and kidney disease among treatment naïve HIV patients at Kano, Nigeria.
Abdu A; Duarte R; Dickens C; Dix-Peek T; Bala SM; Ademola B; Naicker S
PLoS One; 2022; 17(10):e0275949. PubMed ID: 36227935
[TBL] [Abstract][Full Text] [Related]
15. Effects of Testing and Disclosing Ancestry-Specific Genetic Risk for Kidney Failure on Patients and Health Care Professionals: A Randomized Clinical Trial.
Nadkarni GN; Fei K; Ramos MA; Hauser D; Bagiella E; Ellis SB; Sanderson S; Scott SA; Sabin T; Madden E; Cooper R; Pollak M; Calman N; Bottinger EP; Horowitz CR
JAMA Netw Open; 2022 Mar; 5(3):e221048. PubMed ID: 35244702
[TBL] [Abstract][Full Text] [Related]
16. The Apolipoprotein L1 Gene and Cardiovascular Disease.
Robinson TW; Freedman BI
Methodist Debakey Cardiovasc J; 2016; 12(4 Suppl):2-5. PubMed ID: 28298955
[TBL] [Abstract][Full Text] [Related]
17. APOL1 Nephropathy: From Genetics to Clinical Applications.
Friedman DJ; Pollak MR
Clin J Am Soc Nephrol; 2021 Feb; 16(2):294-303. PubMed ID: 32616495
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein L1 Gene Effects on Kidney Transplantation.
Freedman BI; Locke JE; Reeves-Daniel AM; Julian BA
Semin Nephrol; 2017 Nov; 37(6):530-537. PubMed ID: 29110760
[TBL] [Abstract][Full Text] [Related]
19. The Cell Biology of APOL1.
O'Toole JF; Bruggeman LA; Madhavan S; Sedor JR
Semin Nephrol; 2017 Nov; 37(6):538-545. PubMed ID: 29110761
[TBL] [Abstract][Full Text] [Related]
20. COVID-19-Associated Glomerular Disease.
Shetty AA; Tawhari I; Safar-Boueri L; Seif N; Alahmadi A; Gargiulo R; Aggarwal V; Usman I; Kisselev S; Gharavi AG; Kanwar Y; Quaggin SE
J Am Soc Nephrol; 2021 Jan; 32(1):33-40. PubMed ID: 33214201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]